An evaluation of the FDA adverse event reporting system and the potential for reporting bias

被引:5
|
作者
Monnot, Andrew D. [1 ]
Fung, Ernest S. [2 ]
Compoginis, Goli S. [3 ]
Towle, Kevin M. [1 ]
机构
[1] Cardno ChemRisk, 235 Pine St,Suite 2300, San Francisco, CA 94104 USA
[2] Cardno ChemRisk, Aliso Viejo, CA USA
[3] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA
关键词
adverse event reporting; cosmetics; news media;
D O I
10.1111/jocd.14065
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The FDA maintains the Adverse Event Reporting System (CAERS) database, which contains product complaint reports for foods, dietary supplements, and cosmetics. Product line perception and subsequent adverse event reporting may be impacted by negative media attention. Methods The purpose of this analysis was to use the CAERS database to analyze temporal trends in adverse event reporting before and after media coverage of alleged health effects, using WEN by Chaz Dean (WCD) cleansing conditioners as a case study. WCD cleansing conditioner adverse event reports from January 2005 to December 2018 were abstracted from the CAERS database. Zero-inflated negative binomial regression models were used to analyze the rate of adverse events (WCD events/10,000 WCD cleansing conditioner units sold/month), adjusted for temporal trends in CAERS. Results There was a statistically significant higher rate of adverse event reporting after negative media coverage in December 2015 (IRR 16.71 [95% CI: 7.89-35.39]) when compared to the rate of adverse event reporting before December 2015. Conclusions This analysis highlights the importance of assessing potential external factors, such as negative news media coverage, that may alter reporting behaviors due to societal shifts in product-specific risk perception. Consideration of these factors in post-market surveillance programs would result in more comprehensive safety evaluations.
引用
收藏
页码:1849 / 1854
页数:6
相关论文
共 50 条
  • [21] A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
    Zou, Wenbin
    Yang, Han
    Xi, Yu
    Zeng, Chenxi
    Chen, Wei
    Fu, Xiangning
    [J]. HELIYON, 2024, 10 (17)
  • [22] Vaccine Adverse Event Reporting System reporting source: A possible source of bias in longitudinal studies
    Goodman, MJ
    Nordin, J
    [J]. PEDIATRICS, 2006, 117 (02) : 387 - 390
  • [23] Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
    Bai, Yang
    Wu, Bin
    Gou, Liangwen
    Fang, Zhenwei
    Xu, Ting
    Zhang, Tiejun
    Li, Yuwen
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (18)
  • [24] Increased Reporting to the FDA Adverse Event Reporting System (AERS) After Metoclopramidc Black Box Warning
    Sifuentes, Humberto
    Parakkal, Deepak
    Somarriba, Gabriela C.
    Leikin, Jerrold B.
    Ehrenpreis, Eli I.
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S726 - S726
  • [25] Spontaneous reporting of rare events associated with atypical antipsychotics using the FDA adverse event reporting system
    Emechebe, Nnadozie
    Mukhtar, Fahad
    Scheer, Darren
    Patel, Arshiya
    Wadhawan, Abhishek
    Schwartz, Skai
    Zgibor, Janice
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 345 - 346
  • [26] Evaluation of spontaneous adverse event reports for anaemia attributed to atezolizumab within the FDA adverse events reporting system
    Zaafan, Ola
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 460 - 461
  • [27] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [28] Signal detection of adverse reactions for bendamustine based on FDA adverse event reporting system
    Huang, Qing
    Wu, Yuanbin
    Li, Huimin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [29] Evaluation of Ticagrelor Bleeding Adverse Event Reports Compared to Clopidogrel in the FDA Adverse Events Reporting System (FAERS)
    Fahmy, Ahmed I.
    Mekkawy, Mohamed A.
    Abou-Ali, Adel
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 186 - 186
  • [30] Adverse drug reactions in neonates: a brief analysis of the FDA adverse event reporting system
    Byskov, Pernille Kahler
    Baden, Christoffer Storm
    Andersen, Jon Traerup
    Jimenez-Solem, Espen
    Olsen, Ramus Huan
    Gade, Christina
    Lausten-Thomsen, Ulrik
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15